Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678936 | 0.91 | KDM4E (0.48) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL3678934 | 0.91 | KDM4E (0.48) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL14822895 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL13409963 | 0.81 | KMT2A (0.49) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL14069885 | 0.73 | NPC1 (0.51) | SMN1; SMN2GAANPC1RAB9AMAPT | |
| SCHEMBL13409972 | 0.72 | MMP2 (0.50) | — | |
| SCHEMBL13409974 | 0.71 | KMT2A (0.51) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8819957 | 0.70 | RAB9A (0.70) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL12225791 | 0.70 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EGAAMEN1KMT2A | |
| SCHEMBL3679267 | 0.70 | CRAT (0.58) | SMN1; SMN2KDM4EGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | SMN1; SMN2 1205/4885KDM4E 1405/4885GAA 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.